Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Antex Biologics (ANTX)

No earlier versions found for this Subject.

Return to Antex Biologics (ANTX)

Antex Biologics , based in Gaithersburg, MD, is a biopharmaceutical company engaged in developing diagnostics, vaccines,and pharmaceuticals for infectious diseases. Antex's two proprietary core technologies, Adhesin Receptor and Nutriment Signal Transduction, enable Antex to analyze and attack infectious diseases at the beginning of infections, providing the basis for both prevention and treatment. Antex holds corporate alliances with SmithKline Beecham, Pasteur-Merieux Serums et Vaccins, and the U.S. Department of Defense. The Company currently is conducting human clinical trials of vaccines against Campylobacter jejuni, Haemophilus influenzae, and Helicobacter pylori. The company recently changed their name from Microcarb to Antex Biologics to more accurately reflect the company's focus.